<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03067298</url>
  </required_header>
  <id_info>
    <org_study_id>2017-3219</org_study_id>
    <nct_id>NCT03067298</nct_id>
  </id_info>
  <brief_title>Prediction of Preeclampsia and Other Pregnancy Complications Following Combined Iterative Screening</brief_title>
  <acronym>PREDICTION2</acronym>
  <official_title>Prediction of Preeclampsia and Other Pregnancy Complications Following Combined Iterative Screening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emmanuel Bujold</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thermo Fisher Scientific</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preterm birth (PTB), preeclampsia (PE), fetal growth restriction (FGR) and intra-uterine
      fetal death (IUFD) constitutes the main causes of perinatal morbidity and mortality and are
      called &quot;Great Obstetrical Syndromes&quot;. Algorithms to predict those outcomes have been
      developed by combining maternal characteristics (history, age, BMI, blood pressure),
      biochemical (sFlt-1, β-hCG, PlGF, AFP) and sonographic (uterine artery Doppler, 3D of
      placenta, cervical length, nasal bone measurement, nuchal translucency) markers. Another
      prospective observational study (&quot;PREDICTION study&quot; NCT 02189148) is also ongoing, which aims
      to validate those algorithms at the first trimester of pregnancy.

      Recent data suggest that repeating the same measurements later in pregnancy could improve the
      detection rates, allowing closer monitoring of high-risk patients and potential therapeutics
      under investigation. The current study (PREDICTION2) is an ancillary study of PREDICTION and
      aims at validating the use of these markers in a combined iterative manner in the prediction
      of preeclampsia and other obstetrical outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to validate the predictive values of biophysical (maternal
      blood pressure); biochemical (sFlt-1, β-hCG, PlGF, and AFP) and ultrasonographic (cervical
      length, Doppler, 3D evaluation of the placenta, 3D nasal bone) biomarkers at several
      timepoints for the prediction of adverse pregnancy outcomes including preterm birth,
      preeclampsia, fetal growth restriction and intra-uterine fetal death.

      These biomarkers will be evaluated at 14-16 weeks, 20-24 weeks and 30-34 weeks. Those
      specific gestational ages have been selected because they correspond to the typical
      clinical/hospital visits for prenatal blood and/or ultrasound screening.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>preeclampsia</measure>
    <time_frame>&gt;20 weeks of preeclampsia</time_frame>
    <description>1) de novo hypertension with systolic blood pressure ≥ 140 mmHg or diastolic blood pressure &gt;90 mmHg on two occasions at least four hours apart, after 20 weeks of pregnancy, and 2) associated with proteinuria ≥300 mg/24 h or at least '2 +' protein on urine dipstick or an adverse conditions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fetal growth restriction</measure>
    <time_frame>neonatal weight at birth (on the day of birth)</time_frame>
    <description>defined as a birth weight below the 10th centile (or below the 3rd centile for severe FGR) of Canadian reference growth charts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm birth</measure>
    <time_frame>between 20-37 weeks of gestation</time_frame>
    <description>defined as delivery &lt;37 weeks of gestation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra uterine fetal death</measure>
    <time_frame>from the 20th week of gestation to the moment of birth</time_frame>
    <description>fetal death during pregnancy</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Preeclampsia</condition>
  <condition>Preterm Birth</condition>
  <condition>Fetal Growth Restriction</condition>
  <condition>Intra Uterine Fetal Death</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      maternal serum, maternal plasma (cell-free DNA), maternal urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  nulliparous pregnant women participating in Prediction study (NCT02189148)

        Exclusion Criteria:

          -  &lt;18 years old at recruitment;

          -  multiple pregnancies;

          -  fetal congenital malformation;

          -  positive for HIV or hepatitis C;

          -  fetal demise at recruitment;

          -  women planning a delivery outside the participating hospitals;

          -  women not able to provide an informed consent to the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel Bujold, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Quebec</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emmanuel Bujold, MD, MSc</last_name>
    <phone>418-525-4444</phone>
    <phone_ext>47530</phone_ext>
    <email>emmanuel.bujold@crchudequebec.ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sylvie Tapp, MSc</last_name>
    <phone>418-525-4444</phone>
    <phone_ext>46039</phone_ext>
    <email>sylvie.tapp@crchudequebec.ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Bujold, MD, MSc</last_name>
      <phone>418-525-4444</phone>
      <phone_ext>47530</phone_ext>
      <email>emmanuel.bujold@crchudequebec.ulaval.ca</email>
    </contact>
    <contact_backup>
      <last_name>Sylvie Tapp, MSc</last_name>
      <phone>418-525-4444</phone>
      <phone_ext>46039</phone_ext>
      <email>sylvie.tapp@crchudequebec.ulaval.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2017</study_first_submitted>
  <study_first_submitted_qc>February 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>CHU de Quebec-Universite Laval</investigator_affiliation>
    <investigator_full_name>Emmanuel Bujold</investigator_full_name>
    <investigator_title>MD, FRCSC</investigator_title>
  </responsible_party>
  <keyword>pregnancy</keyword>
  <keyword>screening</keyword>
  <keyword>doppler</keyword>
  <keyword>markers</keyword>
  <keyword>PlGF</keyword>
  <keyword>sFlt-1</keyword>
  <keyword>placenta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
    <mesh_term>Fetal Growth Retardation</mesh_term>
    <mesh_term>Fetal Death</mesh_term>
    <mesh_term>Stillbirth</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

